Standout Papers

<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outco... 2016 2026 2019 2022 546
  1. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2016)
    Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology
  2. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation (2017)
    R. Coleman Lindsley, Wael Saber et al. New England Journal of Medicine

Citation Impact

2 by Nobel laureates 13 from Science/Nature 56 standout
Sub-graph 1 of 20

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Open-ST: High-resolution spatial transcriptomics in 3D
2024 Standout
1 intermediate paper

Works of Robert Redd being referenced

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
2019
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
2016 Standout
and 1 more

Author Peers

Author Oncology PFM Hematology Immunology Last Decade Papers Cites
Robert Redd 1455 1237 652 874 100 2.6k
Alessia Arnoldi 6 3 1 1 10 422
Susan E. Gans 2 4 3 13 281
B. Drukker 20 786
K. Pandiselvi 9 386
Sarah H. Walsh 107 220 19 56 9 283

All Works

Loading papers...

Rankless by CCL
2026